Goodbye Biosimilars: Coherus Sells Udenyca To Intas For Half A Billion
Firm Says It Has ‘Completed Strategic Arc’ With Divestment Of Neulasta Rival
Coherus is fully exiting the biosimilars space after striking a final deal worth up to $558m to divest its Udenyca US pegfilgrastim franchise to Accord parent company Intas.
